Radiotherapy trial opens at Beacon

A trial to determine if stereotactic body radiation therapy (SBRT) is superior to hypofractionated intensity modulated radiation therapy (IMRT) in the treatment of localised intermediate risk prostate cancer has opened at the Beacon Hospital in Dublin.

The trial is sponsored in Ireland by NRG Oncology (International) and Cancer Trials Ireland and will recruit 6 to 10 patients per year. The global recruitment target is 622 participants.

Radiation therapy is a treatment option for many cancers, including prostate cancer. There are different methods/techniques used to deliver radiation therapy, two of which are IMRT and SBRT.

This trial aims to discover if SBRT is superior to IMRT in the treatment of localised intermediate risk prostate cancer in terms of genitourinary and gastrointestinal side effects or toxicities. Patients who are eligible for this study will be assigned into either the IMRT or SBRT group on a 1:1 basis. Patients in both groups will be asked to fill out quality of life questionnaires at certain points during the study.

The official title is: NRG GU005 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer. The Principal Investigator in Ireland is Dr Alina Mihai.

Further information